Teva Pharmaceutical Industries Ltd. (TEVA) PT Set at $57.00 by Leerink Swann
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) received a $57.00 target price from analysts at Leerink Swann in a research note issued to investors on Friday. The firm currently has a a “buy” rating on the stock. Leerink Swann’s price target would suggest a potential upside of 25.55% from the company’s current price.
Other equities research analysts also recently issued reports about the company. Goldman Sachs Group Inc. cut their price target on Teva Pharmaceutical Industries from $70.00 to $60.00 in a research note on Sunday, July 17th. HSBC upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Monday, July 18th. Mizuho restated a “buy” rating on shares of Teva Pharmaceutical Industries in a research note on Sunday, July 17th. Jefferies Group lowered their price objective on Teva Pharmaceutical Industries from $72.00 to $69.00 and set a “buy” rating on the stock in a research report on Thursday, July 14th. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $75.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Monday, June 13th. Seven equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $66.98.
Teva Pharmaceutical Industries (NYSE:TEVA) traded down 0.64% on Friday, hitting $45.11. 3,496,752 shares of the company traded hands. Teva Pharmaceutical Industries has a 1-year low of $44.60 and a 1-year high of $66.55. The firm’s 50 day moving average price is $50.28 and its 200 day moving average price is $52.58. The firm has a market capitalization of $41.23 billion, a PE ratio of 30.13 and a beta of 0.74.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/teva-pharmaceutical-industries-ltd-teva-pt-set-at-57-00-by-leerink-swann.html
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.20 by $0.05. The business earned $5 billion during the quarter, compared to the consensus estimate of $4.86 billion. Teva Pharmaceutical Industries had a return on equity of 17.77% and a net margin of 7.56%. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.43 EPS. Equities research analysts predict that Teva Pharmaceutical Industries will post $5.24 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Monday, August 22nd were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date was Thursday, August 18th. Teva Pharmaceutical Industries’s payout ratio is 77.85%.
Several institutional investors have recently bought and sold shares of TEVA. Franklin Resources Inc. increased its position in Teva Pharmaceutical Industries by 11.9% in the second quarter. Franklin Resources Inc. now owns 41,211,549 shares of the company’s stock worth $2,070,095,000 after buying an additional 4,389,590 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC increased its position in Teva Pharmaceutical Industries by 143.7% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 22,700,812 shares of the company’s stock worth $1,140,263,000 after buying an additional 13,385,352 shares during the last quarter. Waddell & Reed Financial Inc. increased its position in Teva Pharmaceutical Industries by 4.9% in the second quarter. Waddell & Reed Financial Inc. now owns 19,358,468 shares of the company’s stock worth $972,375,000 after buying an additional 896,033 shares during the last quarter. Capital Research Global Investors increased its position in Teva Pharmaceutical Industries by 49.6% in the second quarter. Capital Research Global Investors now owns 17,265,800 shares of the company’s stock worth $867,261,000 after buying an additional 5,722,500 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Teva Pharmaceutical Industries by 15.3% in the second quarter. Bank of New York Mellon Corp now owns 14,868,642 shares of the company’s stock worth $746,852,000 after buying an additional 1,972,944 shares during the last quarter. 63.35% of the stock is currently owned by institutional investors and hedge funds.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.
Receive News & Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.